BCYC - CIK 0001761612
BICYCLE THERAPEUTICS plc trades as BCYC. In its fiscal 2025 annual report the company posted revenue of $72.59M, up 105.8% from the prior year and net income of -$218.96M. This page tracks BICYCLE THERAPEUTICS plc through 634 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 8 fiscal years BICYCLE THERAPEUTICS plc's revenue grew from $2.06M to $72.59M, a compound annual growth rate of 56.1%. Net profit margin expanded from -789.3% to -301.7% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Major company event | 8-K | 2026-05-21 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-04 |
| Quarterly report | 10-Q | 2026-04-30 |
| Major company event | 8-K | 2026-04-30 |
| Annual report to shareholders | ARS | 2026-04-22 |
| Proxy statement | DEF 14A | 2026-04-22 |
The largest companies sharing BICYCLE THERAPEUTICS plc's SEC industry classification (pharmaceutical preparations).
BICYCLE THERAPEUTICS plc reported revenue of $72.59M for fiscal year 2025, an increase of 105.8% year over year.
In its latest fiscal year BICYCLE THERAPEUTICS plc reported a net loss of $218.96M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.